Cancer Research Cancer Health Disparities Conference 2009 CR Podcast
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Yang, L.
Right arrow Articles by Cheng, J. Q.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Yang, L.
Right arrow Articles by Cheng, J. Q.
[Cancer Research 64, 4394-4399, July 1, 2004]
© 2004 American Association for Cancer Research

Advances in Brief

Akt/Protein Kinase B Signaling Inhibitor-2, a Selective Small Molecule Inhibitor of Akt Signaling with Antitumor Activity in Cancer Cells Overexpressing Akt

Lin Yang1, Han C. Dan1, Mei Sun1, Qiyuan Liu1, Xia-meng Sun1, Richard I. Feldman2, Andrew D. Hamilton3, Mark Polokoff2, Santo V. Nicosia1, Meenhard Herlyn4, Said M. Sebti1 and Jin Q. Cheng1

1 Department of Pathology and Interdisciplinary Oncology, University of South Florida College of Medicine, H. Lee Moffitt Cancer Center, Tampa, Florida; 2 Berlex Biosciences, Richmond, California; 3 Department of Chemistry, Yale University, New Haven, Connecticut; and 4 The Wistar Institute, Philadelphia, Pennsylvania

Accumulated studies have shown that activation of the Akt pathway plays a pivotal role in malignant transformation and chemoresistance by inducing cell survival, growth, migration, and angiogenesis. Therefore, Akt is believed to be a critical target for cancer intervention. Here, we report the discovery of a small molecule Akt pathway inhibitor, Akt/protein kinase B signaling inhibitor-2 (API-2), by screening the National Cancer Institute Diversity Set. API-2 suppressed the kinase activity and phosphorylation level of Akt. The inhibition of Akt kinase resulted in suppression of cell growth and induction of apoptosis in human cancer cells that harbor constitutively activated Akt due to overexpression of Akt or other genetic alterations such as PTEN mutation. API-2 is highly selective for Akt and does not inhibit the activation of phosphatidylinositol 3'-kinase, phosphoinositide-dependent kinase-1, protein kinase C, serum- and glucocorticoid-inducible kinase, protein kinase A, signal transducer and activators of transcription 3, extracellular signal-regulated kinase-1/2, or c-Jun NH2-terminal kinase. Furthermore, API-2 potently inhibited tumor growth in nude mice of human cancer cells in which Akt is aberrantly expressed/activated but not of those cancer cells in which it is not. These findings provide strong evidence for pharmacologically targeting Akt for anticancer drug discovery.




This article has been cited by other articles:


Home page
 Cardiovasc ResHome page
A. Darmellah, C. Rucker-Martin, and D. Feuvray
ERM proteins mediate the effects of Na+/H+ exchanger (NHE1) activation in cardiac myocytes
Cardiovasc Res, December 15, 2008; (2008) cvn320v2.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
T. Bachleitner-Hofmann, M. Y. Sun, C.-T. Chen, L. Tang, L. Song, Z. Zeng, M. Shah, J. G. Christensen, N. Rosen, D. B. Solit, et al.
HER kinase activation confers resistance to MET tyrosine kinase inhibition in MET oncogene-addicted gastric cancer cells
Mol. Cancer Ther., November 1, 2008; 7(11): 3499 - 3508.
[Abstract] [Full Text] [PDF]

Home page
 Ann. Surg. Oncol.Home page
M. J. Smith, A. C. Culhane, S. Killeen, M. A. Kelly, J. H. Wang, T. G. Cotter, and H. P. Redmond
Mechanisms Driving Local Breast Cancer Recurrence in a Model of Breast-Conserving Surgery
Ann. Surg. Oncol., October 1, 2008; 15(10): 2954 - 2964.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
S. Fernandez de Mattos, P. Villalonga, J. Clardy, and E. W-F. Lam
FOXO3a mediates the cytotoxic effects of cisplatin in colon cancer cells
Mol. Cancer Ther., October 1, 2008; 7(10): 3237 - 3246.
[Abstract] [Full Text] [PDF]

Home page
 J. Pharmacol. Exp. Ther.Home page
Y. Xia, C. Z. Wang, J. Liu, N. C. Anastasio, and K. M. Johnson
Lithium Protection of Phencyclidine-Induced Neurotoxicity in Developing Brain: The Role of Phosphatidylinositol-3 Kinase/Akt and Mitogen-Activated Protein Kinase Kinase/Extracellular Signal-Regulated Kinase Signaling Pathways
J. Pharmacol. Exp. Ther., September 1, 2008; 326(3): 838 - 848.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
R. J. Schilder, M. W. Sill, R. B. Lee, T. J. Shaw, M. K. Senterman, A. J. Klein-Szanto, Z. Miner, and B. C. Vanderhyden
Phase II Evaluation of Imatinib Mesylate in the Treatment of Recurrent or Persistent Epithelial Ovarian or Primary Peritoneal Carcinoma: A Gynecologic Oncology Group Study
J. Clin. Oncol., July 10, 2008; 26(20): 3418 - 3425.
[Abstract] [Full Text] [PDF]

Home page
 Proc. Natl. Acad. Sci. USAHome page
K. Shen, V. K. Thomas, M. L. Dustin, and L. C. Kam
From the Cover: Micropatterning of costimulatory ligands enhances CD4+ T cell function
PNAS, June 3, 2008; 105(22): 7791 - 7796.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
M. A. Tran, C. D. Smith, M. Kester, and G. P. Robertson
Combining Nanoliposomal Ceramide with Sorafenib Synergistically Inhibits Melanoma and Breast Cancer Cell Survival to Decrease Tumor Development
Clin. Cancer Res., June 1, 2008; 14(11): 3571 - 3581.
[Abstract] [Full Text] [PDF]

Home page
 aacredbookHome page
P. A Dennis
Targeting Akt in Cancer: Promise, Progress, and Potential Pitfalls
Am. Assoc. Cancer Res. Educ. Book, April 12, 2008; 2008(1): 25 - 35.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
S. Bakalian, J.-C. Marshall, P. Logan, D. Faingold, S. Maloney, S. Di Cesare, C. Martins, B. F. Fernandes, and M. N. Burnier Jr.
Molecular Pathways Mediating Liver Metastasis in Patients with Uveal Melanoma
Clin. Cancer Res., February 15, 2008; 14(4): 951 - 956.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
H. Yang, W. Kong, L. He, J.-J. Zhao, J. D. O'Donnell, J. Wang, R. M. Wenham, D. Coppola, P. A. Kruk, S. V. Nicosia, et al.
MicroRNA Expression Profiling in Human Ovarian Cancer: miR-214 Induces Cell Survival and Cisplatin Resistance by Targeting PTEN
Cancer Res., January 15, 2008; 68(2): 425 - 433.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
Y. Ren, Z. Chen, L. Chen, N. T. Woods, G. W. Reuther, J. Q. Cheng, H.-g. Wang, and J. Wu
Shp2E76K Mutant Confers Cytokine-independent Survival of TF-1 Myeloid Cells by Up-regulating Bcl-XL
J. Biol. Chem., December 14, 2007; 282(50): 36463 - 36473.
[Abstract] [Full Text] [PDF]

Home page
 MicrobiologyHome page
C.-A. D. Burnham, S. E. Shokoples, and G. J. Tyrrell
Invasion of HeLa cells by group B streptococcus requires the phosphoinositide-3-kinase signalling pathway and modulates phosphorylation of host-cell Akt and glycogen synthase kinase-3
Microbiology, December 1, 2007; 153(12): 4240 - 4252.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Cell. Biol.Home page
Y. Jossin and A. M. Goffinet
Reelin Signals through Phosphatidylinositol 3-Kinase and Akt To Control Cortical Development and through mTor To Regulate Dendritic Growth
Mol. Cell. Biol., October 15, 2007; 27(20): 7113 - 7124.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
C.-H. Lu, S. L. Wyszomierski, L.-M. Tseng, M.-H. Sun, K.-H. Lan, C. L. Neal, G. B. Mills, G. N. Hortobagyi, F. J. Esteva, and D. Yu
Preclinical Testing of Clinically Applicable Strategies for Overcoming Trastuzumab Resistance Caused by PTEN Deficiency
Clin. Cancer Res., October 1, 2007; 13(19): 5883 - 5888.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
J. J. Gills, S. S. Castillo, C. Zhang, P. A. Petukhov, R. M. Memmott, M. Hollingshead, N. Warfel, J. Han, A. P. Kozikowski, and P. A. Dennis
Phosphatidylinositol Ether Lipid Analogues That Inhibit AKT Also Independently Activate the Stress Kinase, p38{alpha}, through MKK3/6-independent and -dependent Mechanisms
J. Biol. Chem., September 14, 2007; 282(37): 27020 - 27029.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Cell Physiol.Home page
F. Meng, R. Henson, and T. Patel
Chemotherapeutic stress selectively activates NF-{kappa}B-dependent AKT and VEGF expression in liver cancer-derived endothelial cells
Am J Physiol Cell Physiol, August 1, 2007; 293(2): C749 - C760.
[Abstract] [Full Text] [PDF]

Home page
 Toxicol PatholHome page
A. M. Sargeant, R. D. Klein, R. C. Rengel, S. K. Clinton, S. K. Kulp, Y. Kashida, M. Yamaguchi, X. Wang, and C.-S. Chen
Chemopreventive and Bioenergetic Signaling Effects of PDK1/Akt Pathway Inhibition in a Transgenic Mouse Model of Prostate Cancer
Toxicol Pathol, June 1, 2007; 35(4): 549 - 561.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
S. V. Madhunapantula, A. Sharma, and G. P. Robertson
PRAS40 Deregulates Apoptosis in Malignant Melanoma
Cancer Res., April 15, 2007; 67(8): 3626 - 3636.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
L. Yang, M. Sun, X.-m. Sun, G. Z. Cheng, S. V. Nicosia, and J. Q. Cheng
Akt Attenuation of the Serine Protease Activity of HtrA2/Omi through Phosphorylation of Serine 212
J. Biol. Chem., April 13, 2007; 282(15): 10981 - 10987.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
Y. Fujiwara, Y. Hosokawa, K. Watanabe, S. Tanimura, K.-i. Ozaki, and M. Kohno
Blockade of the phosphatidylinositol-3-kinase-Akt signaling pathway enhances the induction of apoptosis by microtubule-destabilizing agents in tumor cells in which the pathway is constitutively activated
Mol. Cancer Ther., March 1, 2007; 6(3): 1133 - 1142.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
J. S. Kim, J. I. Eom, J.-W. Cheong, A. J. Choi, J. K. Lee, W. I. Yang, and Y. H. Min
Protein Kinase CK2{alpha} as an Unfavorable Prognostic Marker and Novel Therapeutic Target in Acute Myeloid Leukemia
Clin. Cancer Res., February 1, 2007; 13(3): 1019 - 1028.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Cell Physiol.Home page
M. Alikhani, C. M. MacLellan, M. Raptis, S. Vora, P. C. Trackman, and D. T. Graves
Advanced glycation end products induce apoptosis in fibroblasts through activation of ROS, MAP kinases, and the FOXO1 transcription factor
Am J Physiol Cell Physiol, February 1, 2007; 292(2): C850 - C856.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Cell Physiol.Home page
J. Dong, S. Fujii, S. Imagawa, S. Matsumoto, M. Matsushita, S. Todo, H. Tsutsui, and B. E. Sobel
IL-1 and IL-6 induce hepatocyte plasminogen activator inhibitor-1 expression through independent signaling pathways converging on C/EBP{delta}
Am J Physiol Cell Physiol, January 1, 2007; 292(1): C209 - C215.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
S. Holder, M. Zemskova, C. Zhang, M. Tabrizizad, R. Bremer, J. W. Neidigh, and M. B. Lilly
Characterization of a potent and selective small-molecule inhibitor of the PIM1 kinase
Mol. Cancer Ther., January 1, 2007; 6(1): 163 - 172.
[Abstract] [Full Text] [PDF]

Home page
 IOVSHome page
P. Yang, J. J. Peairs, R. Tano, and G. J. Jaffe
Oxidant-mediated Akt Activation in Human RPE Cells.
Invest. Ophthalmol. Vis. Sci., October 1, 2006; 47(10): 4598 - 4606.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
A. M. Karst, D. L. Dai, J. Q. Cheng, and G. Li
Role of p53 Up-regulated Modulator of Apoptosis and Phosphorylated Akt in Melanoma Cell Growth, Apoptosis, and Patient Survival.
Cancer Res., September 15, 2006; 66(18): 9221 - 9226.
[Abstract] [Full Text] [PDF]

Home page
 CarcinogenesisHome page
K. El-Bayoumy, A. Das, B. Narayanan, N. Narayanan, E. S. Fiala, D. Desai, C. V. Rao, S. Amin, and R. Sinha
Molecular targets of the chemopreventive agent 1,4-phenylenebis (methylene)-selenocyanate in human non-small cell lung cancer
Carcinogenesis, July 1, 2006; 27(7): 1369 - 1376.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
R. Serantes, F. Arnalich, M. Figueroa, M. Salinas, E. Andres-Mateos, R. Codoceo, J. Renart, C. Matute, C. Cavada, A. Cuadrado, et al.
Interleukin-1beta Enhances GABAA Receptor Cell-surface Expression by a Phosphatidylinositol 3-Kinase/Akt Pathway: RELEVANCE TO SEPSIS-ASSOCIATED ENCEPHALOPATHY
J. Biol. Chem., May 26, 2006; 281(21): 14632 - 14643.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Cell. Biol.Home page
Q. Wu, A. M. Ortegon, B. Tsang, H. Doege, K. R. Feingold, and A. Stahl
FATP1 Is an Insulin-Sensitive Fatty Acid Transporter Involved in Diet-Induced Obesity.
Mol. Cell. Biol., May 1, 2006; 26(9): 3455 - 3467.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
Z. Zeng, I. J. Samudio, W. Zhang, Z. Estrov, H. Pelicano, D. Harris, O. Frolova, N. Hail Jr., W. Chen, S. M. Kornblau, et al.
Simultaneous Inhibition of PDK1/AKT and Fms-Like Tyrosine Kinase 3 Signaling by a Small-Molecule KP372-1 Induces Mitochondrial Dysfunction and Apoptosis in Acute Myelogenous Leukemia.
Cancer Res., April 1, 2006; 66(7): 3737 - 3746.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
C. A. Granville, R. M. Memmott, J. J. Gills, and P. A. Dennis
Handicapping the Race to Develop Inhibitors of the Phosphoinositide 3-Kinase/Akt/Mammalian Target of Rapamycin Pathway
Clin. Cancer Res., February 1, 2006; 12(3): 679 - 689.
[Abstract] [Full Text] [PDF]

Home page
 J. Pharmacol. Exp. Ther.Home page
G. E. Avila, X. Zheng, X. X. Cui, A. D. Ryan, A. Hansson, J. Suh, A. B. Rabson, R. L. Chang, W. J. Shih, Y. Lin, et al.
Inhibitory Effects of 12-O-Tetradecanoylphorbol-13-acetate Alone or in Combination with All-trans Retinoic Acid on the Growth of Cultured Human Pancreas Cancer Cells and Pancreas Tumor Xenografts in Immunodeficient Mice
J. Pharmacol. Exp. Ther., October 1, 2005; 315(1): 170 - 187.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
A. Hachem and R. B. Gartenhaus
Oncogenes as molecular targets in lymphoma
Blood, September 15, 2005; 106(6): 1911 - 1923.
[Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
K. N. Thimmaiah, J. B. Easton, G. S. Germain, C. L. Morton, S. Kamath, J. K. Buolamwini, and P. J. Houghton
Identification of N10-Substituted Phenoxazines as Potent and Specific Inhibitors of Akt Signaling
J. Biol. Chem., September 9, 2005; 280(36): 31924 - 31935.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
Y. Luo, A. R. Shoemaker, X. Liu, K. W. Woods, S. A. Thomas, R. de Jong, E. K. Han, T. Li, V. S. Stoll, J. A. Powlas, et al.
Potent and selective inhibitors of Akt kinases slow the progress of tumors in vivo
Mol. Cancer Ther., June 1, 2005; 4(6): 977 - 986.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
A. Shah, W. A. Swain, D. Richardson, J. Edwards, D. J. Stewart, C. M. Richardson, D. E.B. Swinson, D. Patel, J. L. Jones, and K. J. O'Byrne
Phospho-Akt Expression Is Associated with a Favorable Outcome in Non-Small Cell Lung Cancer
Clin. Cancer Res., April 15, 2005; 11(8): 2930 - 2936.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
F. Lefranc, J. Brotchi, and R. Kiss
Possible Future Issues in the Treatment of Glioblastomas: Special Emphasis on Cell Migration and the Resistance of Migrating Glioblastoma Cells to Apoptosis
J. Clin. Oncol., April 1, 2005; 23(10): 2411 - 2422.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
I. Shin, J. Edl, S. Biswas, P. C. Lin, R. Mernaugh, and C. L. Arteaga
Proapoptotic Activity of Cell-Permeable Anti-Akt Single-Chain Antibodies
Cancer Res., April 1, 2005; 65(7): 2815 - 2824.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
D. L. Dai, M. Martinka, and G. Li
Prognostic Significance of Activated Akt Expression in Melanoma: A Clinicopathologic Study of 292 Cases
J. Clin. Oncol., March 1, 2005; 23(7): 1473 - 1482.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
Q. Shi, S. Bao, J. A. Maxwell, E. D. Reese, H. S. Friedman, D. D. Bigner, X.-F. Wang, and J. N. Rich
Secreted Protein Acidic, Rich in Cysteine (SPARC), Mediates Cellular Survival of Gliomas through AKT Activation
J. Biol. Chem., December 10, 2004; 279(50): 52200 - 52209.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 2004 by the American Association for Cancer Research.